Press Releases

Featured Press Releases

BIO Applauds Introduction of Bipartisan…

BIO President and CEO John F. Crowley today released the following statement after a bipartisan group of Senators, Sen. Bob Casey (D-PA), Sen. Markwayne Mullin (R-OK), Sen. Sherrod Brown (D-OH), and Sen. Susan Collins (R-ME), introduced the Creating…

Learn more

BIO International Convention Celebrates Another…

Biotechnology Innovation Organization (BIO) is proud to conclude the 2024 BIO International Convention in San Diego, held last week June 3-6, 2024. 1,400 exhibitors and more than 19,500 attendees from 70 countries came together for four full days of…

Learn more

BIO Recognizes Industry Leaders for…

WASHINGTON - June 5, 2024 – The Biotechnology Innovation Organization (BIO) today announced the winners of the organization’s 2024 Leadership in Agri-Biotechnology Awards — honoring Dr. Annette Kleiser, CEO of Dalan Animal Health, as the recipient…

Learn more

BIO to Offer Complimentary Access to One-on-One Partnering™ During J.P. Morgan Healthcare Conference (“JPM Week”)

September 28, 2017

BIO will offer complimentary access to its proprietary BIO One-on-One Partnering™ during "JPM" week January 7-11, 2018

BIO Statement on California’s Drug Price Reporting & Transparency Bill

September 13, 2017

California Senate Bill 17 is bad for patient and does not deliver on its purported promises

FDA Commissioner, Dr. Scott Gottlieb, to Address BIO Patient and Health Advocacy Summit

September 5, 2017

The head of the United States Food and Drug Administration, Dr. Scott Gottlieb, will be the keynote speaker at the BIO Patient and Health Advocacy Summit, October 2-3 at the Mayflower Hotel in Washington, DC. The annual event brings together…

PhRMA and BIO Initiate Litigation to Challenge Unconstitutional Provisions of Nevada’s SB 539

September 1, 2017

Washington, DC (September 1, 2017) – The Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) today initiated litigation in the United States District Court for the District of Nevada…

BIO Asks EPA To Use a Forward-Looking Methodology in Setting Renewable Fuel Standards

August 31, 2017

BIO today submitted comments on EPA's proposed rule on the Renewable Fuel Standard Program: Standards for 2018 and Biomass-Based Diesel Volume for 2019.

BIO Statement on Nomination of Andrei Iancu to Lead U.S. Patent and Trademark Office

August 29, 2017

Washington, D.C. (August 29, 2017) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement on the nomination of Andrei Iancu to lead the U.S. Patent and Trademark Office:“BIO congratulates Mr…

BIO Applauds Signing of Food and Drug Administration Reauthorization Act (FDARA)

August 18, 2017

Enactment of FDA User Fee package important victory for patients, medical innovation

Fireside Chat Speakers, Programming Announced for 2017 BIO Investor Forum

August 15, 2017

BIO announces programming for the upcoming BIO Investor Conference Oct. 17-18 in San Francisco including Kristina Burow, Managing Director of ARCH Venture Partners and Dr. Richard Scheller, Chief Science Officer & Head of Therapeutics…

BIO: Senate Passage of FDA User Fee Package Important Victory for Patients, Medical Innovation

August 3, 2017

Washington, DC (August 3, 2017) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement regarding passage of the Food and Drug Administration Reauthorization Act (FDARA) by the U.S…

BIO Applauds US Court of Appeals Decision on the Renewable Fuel Standard

July 28, 2017

The U.S. Court of Appeals for the District of Columbia Circuit today supported BIO's argument that the RFS statute does not allow EPA to rely on demand-side factors under the oil industry’s control as a basis for setting annual renewable fuel…

Daily News You Can’t Afford to Miss

Read it in under 3 minutes!

The Good Day BIO newsletter is the only daily newsletter at the intersection of biotech, politics, and policy.